GT Biopharma's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; GT Biopharma is scheduled to report earnings on March 27, 2024, and the estimated EPS forecast is €-2.51. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22
Income Statement	-
Total Revenue	-	-	-	$ 0.00	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	$ -1.99M	$ 39.00K	$ -5.86M	$ -6.88M	$ -2.98M
EBITDA	-	$ 64.00K	$ -5.84M	$ -6.88M	$ -2.98M
Net Income Common Stockholders	$ -1.99M	$ 251.00K	$ -5.58M	$ -6.88M	$ -2.98M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 17.97M	$ 19.95M	$ 16.50M	$ 20.78M	$ 23.73M
Total Assets	$ 18.14M	$ 20.13M	$ 16.74M	$ 21.07M	$ 24.17M
Total Debt	$ 120.00K	$ 147.00K	$ 174.00K	$ 198.00K	$ 223.00K
Net Debt	$ -17.85M	$ -19.80M	$ -16.33M	$ -20.59M	$ -23.50M
Total Liabilities	$ 6.38M	$ 7.03M	$ 5.00M	$ 5.12M	$ 8.73M
Stockholders Equity	$ 11.76M	$ 13.05M	$ 11.73M	$ 15.95M	$ 15.44M
Cash Flow	-
Free Cash Flow	-	$ -2.90M	$ -4.30M	$ -2.92M	$ -2.79M
Operating Cash Flow	-	$ -2.90M	$ -4.30M	$ -2.92M	$ -2.79M
Investing Cash Flow	-	$ -6.99M	$ 7.51M	$ 25.00K	$ 1.08M
Financing Cash Flow	-	$ 6.27M	$ -1.00K	$ 0.00	$ -223.00K

Currency in USD

GT Biopharma Earnings and Revenue History

Income Statement >

GT Biopharma Debt to Assets

Balance Sheet >

GT Biopharma Cash Flow

Cash Flow >

GT Biopharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing